

ABSTRACT OF DISCLOSURE

The present invention provides novel *in vivo* indigestible peptides that are highly absorbable and hardly digestible in living organism when administered orally or through other route, and expected to effectively exhibit functions, such as hypotensive effect, in living organism, and ACE inhibitors prepared with the peptides, and medicine or functional food expected to effectively exhibit hypotensive effect in living organism. The *in vivo* indigestible peptides are dipeptides or tripeptides having Pro at the carboxyl terminals, selected from the group consisting of Ile-Pro, Glu-Pro, Arg-Pro, Gln-Pro, Met-Pro, and Ser-Pro-Pro.